Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan-Dec:19:1536012120934957.
doi: 10.1177/1536012120934957.

Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy

Affiliations
Review

Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy

Liqin Zhu et al. Mol Imaging. 2020 Jan-Dec.

Abstract

Asn-Gly-Arg (NGR) motifs have vasculature-homing properties via interactions with the aminopeptidase N (CD13) expressed on tumor neovasculature. Numerous NGR peptides with different molecular scaffolds have been exploited for targeted delivery of different compounds for imaging and therapy. When conjugated with NGR, complexes recognize the CD13 receptor expressed on the tumor vasculature, which improves the specificity to tumor and avoids systematic toxic reactions. Both preclinical and clinical studies performed with these products suggest that NGR-mediated vascular targeting is an effective strategy for delivering bioactive amounts of cytokines to tumor endothelial cells. For molecular imaging, radiolabeled peptides have been the most successful approach and have been translated into clinic. This review describes current data on radiolabeled tumor vasculature-homing NGR peptides for imaging and therapy.

Keywords: NGR; imaging; radiolabeled; therapy; tumor.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Structure of common NGR peptides.
Figure 2.
Figure 2.
Representative micro positron emission tomography images of mice bearing HT-1080 or HT-29 tumors. Right front flank images shown 4 hours after intravenous (IV) administration of 64Cu-DOTA-NGR1 or 64Cu-DOTA-NGR2. The blocking study was performed by IV injection of 64Cu-DOTA-NGR1 or 64Cu-DOTA-NGR2 with coinjection of NGR peptide [c(CNGRC)] in HT-1080 tumor xenografts. It suggested a nearly 2-fold higher CD13 avidity of 64Cu-DOTA-NGR2 than the corresponding monomeric 64Cu-DOTA-NGR1 in HT-1080 cells. Adapted with permission from Kai Chen et al.44 Copyright (2019) America Chemical Society.
Figure 3.
Figure 3.
Representative image of mice bearing HT-1080 or HT-29 tumors after intravenous administration of 68Ga-NOTA-G3-NGR2 or 68Ga-NOTA-G3-RGD2 at 1 hour postinjection, and the coinjection of nonlabeled NOTA-G3-NGR2 or NOTA-G3-RGD2 as blocking agents. Tumors are indicated using circles. There is no significant difference between the 2 probes in terms of tumor uptake based on micro positron emission tomography imaging. Adapted with permission from Yahui Shao et al.46 Copyright (2019) America Chemical Society.

Similar articles

Cited by

References

    1. Wickstrom M, Larsson R, Nygren P, Gullbo J. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci. 2011;102(3):501–508. - PMC - PubMed
    1. Renata P, Erkki K, Renate K, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis 1. Cancer Res. 2000;60(3):722–727. - PMC - PubMed
    1. Angelo C, Curnis F. Tumor vasculature targeting through NGR peptide-based drug delivery systems. Curr Pharm Biotechnol. 2011;12(8):1128–1134. - PubMed
    1. Flavio C, Anna G, Angelina S, Cattaneo A, Magni F, Corti A. Targeted delivery of IFN; to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res. 2005;65(7):2906–2913. - PubMed
    1. Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood. 2008;112(7):2628–2635. - PMC - PubMed

LinkOut - more resources